C6orf103 Inhibitors
Chemical inhibitors of C6orf103 function through various intracellular signaling pathways by selectively targeting and inhibiting key enzymes and receptors that regulate cellular processes. Wortmannin and LY294002, both of which inhibit phosphatidylinositol 3-kinase (PI3K), can directly impact the activity of C6orf103 by preventing the phosphorylation events necessary for the activation of downstream targets including AKT. This results in a reduction of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels, which is essential for the proper functioning of C6orf103 within the PI3K/AKT pathway. Rapamycin, by inhibiting mTOR, can affect processes such as cell growth and survival where C6orf103 is implicated, leading to an indirect inhibition of its function. Similarly, PD98059 targets MEK1/2, key kinases in the MAPK/ERK pathway, and its inhibitory effect can extend to the functions of C6orf103 that are connected to this pathway.
Further inhibitors such as SB203580 and SP600125 target the stress-activated MAP kinases p38 and JNK, respectively. By inhibiting these kinases, SB203580 and SP600125 can suppress the function of C6orf103, assuming it is involved in cellular responses to stress mediated by these pathways. PP2, focusing on Src family tyrosine kinases, and Dasatinib, which targets BCR-ABL and Src kinases, can both inhibit the function of C6orf103 if its activity is regulated by these kinase families. The EGFR inhibitors Erlotinib and Gefitinib disrupt signaling that could be vital for the functions of C6orf103, implicating a decrease in its activity upon their administration. Lastly, IC-87114 and LY333531, by selectively inhibiting PI3Kδ and PKCβ respectively, can impact the role of C6orf103 within the signaling networks these enzymes participate in, leading to a reduction in the functional activity of C6orf103.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a steroidal metabolite of fungi and acts as a potent and irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), which is key in various signaling pathways. Since C6orf103 is involved in signaling pathways that are regulated by PI3K, inhibition of PI3K by Wortmannin could result in decreased C6orf103 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a synthetic molecule that inhibits PI3K, leading to a decrease in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels and subsequent inhibition of AKT signaling. Given that C6orf103 functions within the PI3K/AKT pathway, the inhibition of PI3K by LY294002 is expected to suppress C6orf103 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a macrolide compound that inhibits mTOR (mechanistic target of rapamycin) by binding to its intracellular receptor FKBP12. The mTOR pathway is involved in cell growth and survival, processes in which C6orf103 may be implicated. Thus, inhibition of mTOR by Rapamycin can inhibit the function of C6orf103. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a synthetic compound that specifically inhibits MEK1/2, which are upstream kinases in the MAPK/ERK pathway. Since C6orf103 is known to be associated with the MAPK/ERK pathway, the inhibition of MEK by PD98059 would lead to functional inhibition of C6orf103. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a pyridinyl imidazole derivative that selectively inhibits p38 MAP kinase. The p38 MAP kinase pathway is involved in stress responses, and by inhibiting this pathway, SB203580 can inhibit the function of C6orf103, which is known to be involved in cellular stress responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK), which modulates various cellular activities. Inhibition of JNK by SP600125 would lead to functional inhibition of C6orf103 if JNK signaling is part of its functional repertoire. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases are involved in multiple cell signaling pathways, including those regulating cell proliferation and survival, where C6orf103 might have a role. Inhibition of Src kinases by PP2 could thus inhibit C6orf103 function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with specificity for BCR-ABL and Src family kinases. By inhibiting these kinases, Dasatinib could decrease C6orf103 activity, provided that C6orf103’s function is regulated by these kinases' activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR signaling is involved in cell proliferation and survival. As C6orf103 is involved in similar cellular processes, inhibition of EGFR by Erlotinib could result in the inhibition of C6orf103 function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that works by binding to the tyrosine kinase domain of the receptor. Since C6orf103 is associated with pathways involving EGFR, inhibition of EGFR by Gefitinib could lead to functional inhibition of C6orf103. | ||||||